Key result
Fixed-dose combination antihypertensives had much higher average monthly drug costs than their respective free combinations when the latter were generically available.
Why the study?
Do fixed-dose combinations (FDCs) of antihypertensive drugs reduce average monthly drug costs compared to free combinations (FCs)?
Observational
Yes
Do fixed-dose combinations (FDCs) of antihypertensive drugs reduce average monthly drug costs compared to free combinations (FCs)?
The cost advantage of fixed-dose combination antihypertensives over free combinations is reversed when generic single-agent drugs become available.
Answers are grounded in this paper and cite their sources.
Generic free combinations may cost far less than FDCs; challenges cost-saving assumptions and leaves open adherence-economic tradeoffs.
BACKGROUND: The use of fixed-dose combinations (FDCs) has been increasing since the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended using ≥2 drugs as the first-line drug therapy for patients with stage 2 hypertension. FDCs simplify the drug therapy regimen and reportedly lower the drug therapy cost compared with the free combination (FC) of 2 single-agent drugs. This study hypothesized that the affordability of FDCs over FCs would change over time depending on the availability of generic single-agent drugs. METHODS: This study used the 2009 Medical Expenditure Panel Survey. Antihypertensive drugs were identified based on the Food and Drug Administration national drug directory. Based on the 2 databases, regression models were run to predict average monthly drug cost as well as out-of-pocket cost for each prescription along with their 95% confidence intervals (CIs). RESULTS: Overall, FDCs (n = 26) had average monthly drug costs similar to respective FCs when FCs were not generically available. However, when FCs were generically available, FDCs (n = 11) had average drugs costs much higher than their respective FCs. For example, Lotrel as an FDC had an average monthly drug cost of $115.97 (95% CI = $96.59-$135.36), whereas its counterpart FC had an average monthly drug cost of $21.00 (95% CI = $18.23-$23.79). CONCLUSIONS: The cost advantage of FDCs over FCs was reversed when FCs were generically available. The finding of this study informs patients, health-care providers, and drug plans of the importance of making dynamic decisions on preferred drug therapy options depending on the availability of generic drugs.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2013) conducted an observational in Hypertension. Fixed-dose combination antihypertensive drugs vs. Free combination of single-agent drugs was evaluated on Average monthly drug cost. Fixed-dose combination antihypertensives had much higher average monthly drug costs than their respective free combinations when the latter were generically available.
Synapse has enriched 10 related papers. Consider them for comparative context: